Choi Michael Y, Kashyap Manoj Kumar, Kumar Deepak
Moores Cancer Center, UCSD-Moores Cancer Center, La Jolla, 92093-0820, CA, USA.
Best Pract Res Clin Haematol. 2016 Mar;29(1):40-53. doi: 10.1016/j.beha.2016.08.007. Epub 2016 Aug 11.
Malignant B cells accumulate in the peripheral blood, bone marrow, and lymphoid organs of patients with chronic lymphocytic leukemia (CLL). In the tissue compartments, CLL shape a protective microenvironment by coopting normal elements. The efficacy of drugs that target these interactions further underscores their importance in the pathogenesis of CLL. While the B cell receptor (BCR) pathway clearly plays a central role in the CLL microenvironment, there is also rationale to evaluate agents that inhibit other aspects or modulate the immune cells in the microenvironment. Here we review the main cellular components, soluble factors, and signaling pathways of the CLL microenvironment, and highlight recent clinical advances. As the BCR pathway is reviewed elsewhere, we focus on other aspects of the microenvironment.
恶性B细胞在慢性淋巴细胞白血病（CLL）患者的外周血、骨髓和淋巴器官中积聚。在组织区室中，CLL通过拉拢正常成分形成一个保护性微环境。靶向这些相互作用的药物的疗效进一步强调了它们在CLL发病机制中的重要性。虽然B细胞受体（BCR）通路在CLL微环境中显然起着核心作用，但也有理由评估抑制微环境中其他方面或调节免疫细胞的药物。在这里，我们综述了CLL微环境的主要细胞成分、可溶性因子和信号通路，并强调了最近的临床进展。由于BCR通路在其他地方已有综述，我们将重点关注微环境的其他方面。
